David Goddard, MD
Rheumatology · Brooklyn, NYNPI 1346249844
Payments from drug & device makers
Across 524 payments — averaging $7437.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$739K
- Eli Lilly$540K
- UCB SA$498K
- E.r. Squibb & Sons, L.L.C.$338K
- AbbVie$334K
- Amgen$303K
- plus $1.1M from 14 others
Across 3 payments — averaging $274.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$823
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 25 | $739,127 |
| Eli Lilly | 36 | $540,463 |
| UCB SA | 64 | $498,404 |
| E.r. Squibb & Sons, L.L.C. | 20 | $337,985 |
| AbbVie | 66 | $334,065 |
| Amgen(2 entities) | 13 | $303,318 |
| GSK | 80 | $288,294 |
| Astrazeneca UK Limited | 29 | $203,893 |
| Janssen Research & Development, LLC | 80 | $191,284 |
| Pfizer | 59 | $169,823 |
| Bristol Myers Squibb | 2 | $124,067 |
| Gilead | 25 | $56,754 |
| Sanofi US Services Inc. | 9 | $55,944 |
| AstraZeneca | 2 | $48,386 |
| Aurinia Pharma U.S., Inc. | 3 | $2,454 |
| Karyopharm Therapeutics Inc. | 1 | $1,199 |
| Argenx US, Inc. | 7 | $1,133 |
| Vertex | 1 | $500 |
| Genentech, Inc. | 1 | $53 |
| Johnson & Johnson | 1 | $13 |
How this compares
$3,897,161 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Brooklyn
- Amit SaxenaNew York$6.7M
- Cynthia AranowManhasset$5.3M
- Richard FurieNew Hyde Park$4.3M
- Robert SpieraNew York$4.3M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.